ENGN Insider Trading

Insider Ownership Percentage: 13.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $786,480.75

enGene Insider Trading History Chart

This chart shows the insider buying and selling history at enGene by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

enGene Share Price & Price History

Current Price: $8.65
Price Change: Price Decrease of -0.35 (-3.89%)
As of 06/17/2024 05:19 PM ET

This chart shows the closing price history over time for ENGN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

enGene Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/22/2024De Solidarite Des Travai FondsMajor ShareholderSell47,854$15.00$717,810.003,036,153View SEC Filing Icon  
4/18/2024De Solidarite Des Travai FondsMajor ShareholderSell4,575$15.01$68,670.753,084,107View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for enGene (NASDAQ:ENGN)

64.16% of enGene stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ENGN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

enGene Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/16/2024Janus Henderson Group PLC1,000,000$17.10M0.0%N/A2.295%Search for SEC Filing on Google Icon
5/15/2024Altitude Crest Partners Inc.120,289$2.04M0.9%N/A0.276%Search for SEC Filing on Google Icon
3/7/2024Fcpm Iii Services B.V.8,677,951$80.10M23.8%N/A37.408%Search for SEC Filing on Google Icon
2/15/2024Omega Fund Management LLC1,131,175$10.44M8.5%N/A4.876%Search for SEC Filing on Google Icon
2/15/2024BVF Inc. IL2,251,037$20.78M0.5%N/A9.703%Search for SEC Filing on Google Icon
2/7/2024Vivo Capital LLC678,705$6.26M0.5%N/A2.925%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
enGene logo
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Read More on enGene

Today's Range

Now: $8.65
Low: $8.61
High: $9.08

50 Day Range

MA: $13.20
Low: $7.70
High: $16.28

52 Week Range

Now: $8.65
Low: $6.69
High: $43.00


211,282 shs

Average Volume

66,061 shs

Market Capitalization

$376.97 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of enGene?

enGene's top insider investors include:
  1. De Solidarite Des Travai Fonds (Major Shareholder)
Learn More about top insider investors at enGene.

Who are the major institutional investors of enGene?

enGene's top institutional shareholders include:
  1. Janus Henderson Group PLC — 2.29%
  2. Altitude Crest Partners Inc. — 0.28%
Learn More about top institutional investors of enGene stock.

Which institutional investors are buying enGene stock?

In the previous quarter, ENGN stock was purchased by institutional investors including:
  1. Janus Henderson Group PLC
  2. Altitude Crest Partners Inc.